1 / 52

Optimizing Treatment for HER2-Positive Advanced Breast Cancer

Optimizing Treatment for HER2-Positive Advanced Breast Cancer. Program Goals. CLEOPATRA Study Design. First-Line Therapy of HER2+ MBC. Therapy of MBC After Progression on First-Line Anti-HER2 Treatment. EMILIA: PFS. EMILIA: OS at Second Interim Analysis. EMILIA: Hematologic Adverse Events.

guido
Télécharger la présentation

Optimizing Treatment for HER2-Positive Advanced Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Optimizing Treatment forHER2-Positive Advanced Breast Cancer

  2. Program Goals

  3. CLEOPATRA Study Design

  4. First-Line Therapy of HER2+ MBC

  5. Therapy of MBC After Progression on First-Line Anti-HER2 Treatment

  6. EMILIA: PFS

  7. EMILIA: OS at Second Interim Analysis

  8. EMILIA: Hematologic Adverse Events

  9. First-Line Treatment With T-DM1 vs Trastuzumab + Docetaxel

  10. BOLERO-3: Previous Therapy

More Related